Leading U.S. Diagnostics Laboratory Selects Valkit.ai to Modernize Validation

Enterprise diagnostics lab with revenues of more than $700M USD moves from document-heavy validation to connected, risk-based digital assurance

INDIANAPOLIS, IN, UNITED STATES, October 27, 2026 /EINPresswire.com/ -- alkit.ai today announced that a leading U.S. clinical diagnostics laboratory organization, with annual revenues of more than $700M USD, has selected the Valkit platform to modernize its validation program.

Diagnostics laboratories operate under constant pressure. Results must be fast and accurate, systems must remain in a validated state, and every decision must hold up when an inspector asks to see the evidence. For years, the industry's answer has been documents: Word templates, PDFs and signatures on paper-shaped records. Many "digital" tools simply move those same documents onto a screen.

The organization chose Valkit to move beyond document-centric validation toward a structured, risk-based digital approach. Requirements, risks, test execution, evidence and approvals will live in one connected platform, with traceability built in from the start rather than assembled at the end.

Key reasons for the selection include:

Structured, risk-based validation. Requirements, risks, testing, evidence and approvals are managed together in a single platform instead of being scattered across files and folders.

Built-in traceability. Every requirement connects to its risk, its test and its evidence, so traceability is part of the work itself.

Governance that fits the operating model. Valkit's organization model lets license holders structure and control their validation workspaces to match their own quality procedures. Valkit does not force one structure on every team, so company-wide oversight and team-level accountability can both stand up to inspection.

Reuse instead of rework. Validated content, templates and assets can be reused across systems and projects, so teams stop rebuilding the same deliverables from scratch.

People stay accountable. Valkit's AI assists by proposing, drafting and flagging. Qualified people remain responsible for interpretation, risk acceptance and release decisions, as assurance in a GxP environment requires.

"Diagnostics laboratories work under real pressure: speed, accuracy and regulatory scrutiny all at once," said Stephen Ferrell, Co-Founder and Chief Product Officer of Valkit.ai. "We're proud to support a team that wants validation to be faster and more defensible, and to keep qualified people in control of every decision."

Organizations of this size do not change validation platforms lightly. The decision reflects a broader industry shift: digital assurance is no longer an experiment but is becoming the expected way to work. Modernization does not have to mean rip-and-replace. It means proportionate, risk-based effort, connected evidence and records that are defensible by design.

The customer joins a growing community of life-sciences, laboratory and manufacturing organizations using Valkit for computerized system validation, Computer Software Assurance (CSA), and equipment and laboratory assurance.

Organizations interested in modernizing their validation programs can request a demo at valkit.ai.

About Valkit.ai

Valkit.ai is a life-sciences compliance software company that helps regulated organizations replace document-heavy validation with connected, risk-based digital assurance. The Valkit platform brings requirements, risk, testing, evidence and approvals together with built-in traceability and human-governed AI assistance, supporting computerized system validation, CSA, and equipment and laboratory assurance.

Lisa Silva
Valkit.ai LLC
+1 8889120190
Visit us on social media:
LinkedIn